Framingham genetic testing firm lands $41.5M in funding
Variantyx CEO Haim Neemran
Variantyx, a Framingham firm specializing in advanced genomic testing for rare genetic disorders, reproductive health, and precision oncology, has secured $41.5 million in additional funding to advance its rapidly growing global precision oncology business.
Variantyx’s precision oncology solution uses multiple genomic technologies to analyze and identify the unique genetic alterations to help predict their response to various therapies.
The series C-2 funding round was led by international investors including New Era Capital Partners, Peregrine Ventures, Robert Bosch Venture Capital, and Pitango HealthTech. One of its other investors is 20/20 HealthCare Partners based in Massachusetts.
The funding denotes the continuation of the long-standing relationship between Variantyx and New Era Capital Partners.
"It allows us to expand our diagnostic solutions to a wider array of customers so that medical care can become more personalized," said Haim Neerman, CEO of Variantyx. "The growth of Variantyx has been exponential, and we look forward to sharing the new disruptive products we have in the pipeline."
WBJ Web Partners
Most Recent
Most Recent
0 Comments